StockpollyBeta
Get App
Popularity #3,955
ALDX · NASDAQ · Biotechnology

Aldeyra Therapeutics (ALDX)

Develops RASP modulators and ophthalmology candidates for immune-mediated diseases.

$1.35
vs last close−0.04 (−3.23%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
106918161710108736
Research & development746151215795423
32334232321,137,3432
General & administrative32334232321,137,3432
Other expenses0000000000−1,137,3420
Operating income−10−6−9−18−16−17−10−10−8−7−4−6
111111000000
Interest income222221111110
Interest expense110000000000
Other non-operating income−2−2−2−2−2−1−1−1−1−1−10
Income before tax−8−5−8−17−15−16−10−10−8−6−3−5
Net income from continuing operations−8−5−8−17−15−16−10−10−8−6−3−5
Net income−8−5−8−17−15−16−10−10−8−6−3−5
EPS, basic−$0.14−$0.08−$0.14−$0.28−$0.25−$0.27−$0.17−$0.16−$0.13−$0.11−$0.06−$0.09
EPS, diluted−$0.14−$0.08−$0.14−$0.28−$0.25−$0.27−$0.17−$0.16−$0.13−$0.11−$0.06−$0.09
Weighted average shares, basic595959596059606060606060
Weighted average shares, diluted595959596059606060606060
EBITDA−8−4−8−16−15−15−9−9−7−6−3−5
Depreciation & amortization000000000000
EBIT−8−4−8−16−15−15−9−9−7−6−3−5